GSK Investigational Site

Windsor, Ontario N9C 3Z4

1 studies enrolling now · 35 studies all time

What they study most

Arthritis, Rheumatoid, Asthma, Cough, Crohn's Disease, Dermatitis, Atopic, Diabetes Mellitus, Type 2, Nausea, Nausea and Vomiting, Chemotherapy-Induced, Psoriasis, Pulmonary Disease, Chronic Obstructive, Refractory Chronic Cough, Schizophrenia

Studies at this site

• eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation — Recruiting now
• A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough — Completed
• A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough — Running, not enrolling
• A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma — Running, not enrolling
• A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype — Completed
• Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma — Running, not enrolling
• A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma — Completed
• Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level — Completed
• Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma — Completed
• Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype — Completed
• Study of Mepolizumab Autoinjector in Asthmatics — Completed
• Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) — Stopped early
• A Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Maintenance Therapy in Poorly Controlled Asthmatic Subjects — Completed
• A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma — Completed
• An Open-label Study to Evaluate Correct Use and Ease of Use of the ELLIPTA DPI in Pediatric Subjects With Asthma — Completed
• Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma — Completed
• A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients — Completed
• A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients — Completed
• Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD) — Completed
• SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma. — Completed
• Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma — Completed
• Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control — Completed
• Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease — Completed
• 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old — Completed
• Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide — Completed
• A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD) — Completed
• A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis — Completed
• COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis — Completed
• Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia — Completed
• Cross-sectional Study for Identification and Description of Severe Asthma Patients — Completed
• Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease — Completed
• Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting — Completed